Progestin News and Research

RSS

Injectable form of progestin may increase breast cancer risk in young women

The first large-scale U.S.-based study to evaluate the link between an injectable form of progestin-only birth control and breast cancer risk in young women has found that recent use of a year or more doubles the risk.

5 Apr 2012

Hormones use and breast cancer risk

...

1 Apr 2012

Estrogen only HRT in some postmenopausal women could lower breast cancer risk: Study

...

8 Mar 2012

Bayer receives FDA approval for lower dose formulation of ANGELIQ

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a lower dose formulation of ANGELIQ (drospirenone and estradiol) tablets to treat moderate to severe vasomotor symptoms due to menopause in women who have a uterus.

29 Feb 2012

Quitting hormone therapy can lead to breast tumor regression

As soon as women quit hormone therapy, their rates of new breast cancer decline, supporting the hypothesis that stopping hormones can lead to tumor regression, according to a report e-published in Cancer Epidemiology, Biomarkers, & Prevention.

29 Feb 2012

DMPA intake may increase risk of periodontitis, gingivitis in women

Injectable progesterone contraceptives may be associated with poor periodontal health, according to research in the Journal of Periodontology. The study found that women who are currently taking depotmedroxyprogesterone acetate (DMPA) injectable contraceptive, or have taken DMPA in the past, are more likely to have indicators of poor periodontal health, including gingivitis and periodontitis, than women who have never taken the injectable contraceptive.

7 Feb 2012

Breast cancer risks and management updates

A new report that looks at the environmental factors that affect risk of breast cancer is out. It suggests that women can reduce their risk by avoiding unnecessary medical radiation, forgoing hormone treatments for menopause that combine estrogen and progestin, limiting alcohol intake and minimizing weight gain.

8 Dec 2011

Combo hormone therapy increases risk of breast cancer in women with new-onset tenderness

The debate about using menopausal hormone therapies to relieve symptoms in post-menopausal women has been ongoing. Is the combination therapy of estrogen and progestin better or worse than just giving women estrogen alone? In women who still have a uterus (those who have not had a hysterectomy), progestin counteracts the increased risk of uterus cancer when estrogen is given alone, but at the expense of an increase in breast cancer risk compared to estrogen alone.

19 Nov 2011

Merck's NEXPLANON 68 mg now available in the U.S.

Merck today announced that NEXPLANON (etonogestrel implant) 68 mg, a long-acting, progestin-only single-rod hormonal contraceptive, is now available in the United States.

10 Nov 2011

New onset tenderness after combo hormone therapy increases risk of breast cancer

Post-menopausal women who experience new onset breast tenderness after starting combination hormone therapy may have an increased risk of breast cancer compared to women who don't experience breast tenderness, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center has shown.

15 Oct 2011

LA BioMed andrologist leads new male contraceptive Phase I clinical study

Christina Wang, M.D., lead investigator at Los Angeles Biomedical Research Institute (LA BioMed) - one of the leading biomedical research institutes in the country - is currently working on a Phase I single dose and multiple dose study that tests the safety and tolerability of a new androgen dimethandrolone undecanoate that is being developed as a potential male contraceptive agent.

20 Sep 2011

Teva's ZOELY oral contraceptive receives EU Marketing Authorization

Teva Pharmaceutical Industries Ltd announced today that its new oral contraceptive, ZOELY, has received a Marketing Authorization in the European Union (EU) for the prevention of pregnancy.

2 Aug 2011

Post-menopausal women with CAD are at increased risk for SCD: Study

A new study from the Perelman School of Medicine at the University of Pennsylvania indicates that post-menopausal women with coronary artery disease and other risk factors are at an increased risk for sudden cardiac death.

30 Jul 2011

Birth control pill safety issues raised

The U.S. Food and Drug Administration (FDA) has announced that it is looking at results from two studies that showed there is a higher risk of blood clots in women taking new birth control pills containing the compound drospirenone. Some brand names include Yaz, Yasmin, Beyaz, Ocella, Loryna, Gianvi, Safyral, Syeda and Zarah.

1 Jun 2011

EMAS publishes position statement on women's post-reproductive health problems in Maturitas journal

Elsevier announced the publication of an important position statement from the European Menopause and Andropause Society in the journal Maturitas on managing menopausal women with a personal or family history of venous thromboembolism.

18 May 2011

Watson launches Generess Fe low-dose oral contraceptives in the U.S.

Watson Pharmaceuticals, Inc., today announced the U.S. commercial launch of Generess Fe 0.8 mg/25 mcg, a new low-dose oral contraceptive option that's highly effective at preventing pregnancy and proven to provide users with short, lighter, predictable periods.

2 May 2011

Bayer's oral contraceptives may increase risk of blood clots, stroke or heart attack

Bayer HealthCare Pharmaceuticals, Inc. is aware of two studies published today in The British Medical Journal, ONLINE FIRST.

25 Apr 2011

Bayer's birth control pills may increase risk of venous thromboembolism

The following release is being issued by law firms RodaNast, P.C.; Levin, Fishbein, Sedran & Berman and Feldman & Pinto: According to two new studies published in the online edition of the British Medical Journal, Bayer's birth control pills Yaz and Yasmin, containing a new progestin drospirenone, carry up to triple the risk of serious blood clots over traditional pills containing the progestin levonorgestrel.

25 Apr 2011

A4M: Estrogen helps prevent risk of breast cancer in women

After timely breaking news this week about a study showing that estrogen lowers breast cancer risk in women, The American Academy of Anti-Aging Medicine could have almost started its 19th Annual Conference here today saying "I told you so."

11 Apr 2011

Estrogen only hormone replacement not so risky after 50’s: Study

According to a new study hormone therapy may not be as risky for elder women as earlier thought. This comes from the Women's Health Initiative, a federally funded trial that tracked thousands of women taking hormones or placebo pills for years. The WHI looked at women who have had hysterectomies or have had their uterus removed and thus can take estrogen unaccompanied by another hormone, progestin. It found that a heightened risk of stroke from taking estrogen faded with time, while a reduced risk of breast cancer held steady.

5 Apr 2011